Financial Performance Highlights
Jupiter Life Line Hospitals Limited reported strong FY26 performance with revenue from operations reaching ₹1,499.78 crore (₹11,976.24 million), up from ₹1,302.40 crore in FY25, representing a 15% CAGR from FY21 to FY26. Net profit stood at ₹194.20 crore (₹1,913.80 million) compared to ₹193.80 crore in FY25, maintaining a 31% CAGR over the same period. EBITDA reached ₹343.30 crore with margins of 22.89% (slightly down from 23.50% in FY25). The company declared an interim dividend of ₹1 per equity share (10% on face value of ₹10) totaling ₹65.57 million.
Operational and Expansion Metrics
The company operationalized its 500-bed Dombivli hospital in February 2026 with a ₹425 crore investment, delivered 25 months ahead of schedule. The facility features 30+ clinical specialties including cardiac sciences, oncology, neurosciences, and organ transplant services, with expected EBITDA breakeven by end of second year. Operational metrics showed average occupancy rate of 61.2% (62.3% excluding Dombivli), ARPOB of ₹67,700, and ALOS of 3.87 days. Pipeline projects include Pune South (200-220 beds, construction began Q3 FY26), Mira Road (300 beds), and BKC Mumbai (400 beds) toward a long-term target of ~3,000 bed integrated healthcare platform.
Capital Structure and Corporate Actions
Significant capital expenditure of ₹434.38 crore included additions to property, plant and equipment and capitalization of Dombivli Hospital at ₹388.13 crore. The board provided corporate guarantee to HDFC Bank for subsidiary Jupiter Hospital Projects Private Limited borrowing up to ₹250 crore. The company maintained a debt-equity ratio of 0.16 and current ratio of 3.63. Implementation of new Labour Codes resulted in ₹43.89 million exceptional item for increased gratuity liability. Application filed with NCLT for amalgamation of Medulla Healthcare with the Company.
Corporate Governance and Compliance
The 24th Annual General Meeting will be held on July 17, 2026 through video conferencing. The 9-member Board includes 2 Executive Directors and 7 Non-Executive Directors (5 Independent). Key management includes Dr. Ankit Thakker as MD & CEO, Mr. Sivasis Sen as CFO, and Ms. Suma Upparatti as Company Secretary. The company maintained compliance with SEBI (LODR) Regulations, 2015, with contingent liabilities of ₹36.22 million in pending litigations and MSME dues of ₹254.52 million payable as of March 31, 2026.
Subsidiaries and Credit Rating
Key subsidiaries include Jupiter Hospital Projects Private Limited (96.56% owned, material subsidiary), Medulla Healthcare Private Limited (100% owned), and Jupiter Hospital Pharmacy Private Limited (95% owned). Credit rating was upgraded to [ICRA]AA- (Stable) from [ICRA]A+ with short-term scale reaffirmed at [ICRA]A1+. Total workforce stood at 3,002 employees with employee benefits expense of ₹195.85 crore.
Sustainability and Forward Outlook
CSR expenditure of ₹4.06 crore focused on community health, education, and sports development. Environmental initiatives included renewable energy adoption reducing emissions by 2,991 metric tonnes CO₂e, Zero Liquid Discharge systems, and improved water and energy intensity metrics. The company continues expansion with construction of new hospitals in Bibvewadi, Pune and Mira Road, Thane, and land agreement with MMRDA for BKC Mumbai hospital, positioning for continued growth in the healthcare services sector.